New obesity drug candidate enters early safety testing
NCT ID NCT07232732
First seen Nov 18, 2025 · Last updated Jun 16, 2026 · Updated 23 times
Summary
This early-stage study tests a new drug called LY3549492 in 120 healthy adults who are overweight or have obesity. The main goal is to check the drug's safety and how the body processes it over about 8 weeks. Participants receive multiple doses of the drug, and researchers monitor for side effects and drug levels in the blood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fortrea Clinical Research Unit
Daytona Beach, Florida, 32117, United States
-
Fortrea Clinical Research Unit
Dallas, Texas, 75247, United States
-
Fortrea Clinical Research Unit
Madison, Wisconsin, 53704, United States
Conditions
Explore the condition pages connected to this study.